Eli Lilly’s (LLY.N), opens new tab blood cancer treatment Jaypirca helped patients live longer without the disease getting worse, the U.S. drugmaker said on Monday, meeting the main goal in a late-stage study in previously untreated patients.
The drug, chemically known as pirtobrutinib, was tested in patients with a type of chronic lymphocytic leukemia, or small lymphocytic lymphoma (CLL/SLL), compared to chemoimmunotherapy.
The disease is characterized by an increased production of abnormal white blood cells that have difficulty fighting infections.
Jaypirca is currently approved for patients with CLL/SLL and mantle-cell lymphoma, a rare type of blood cancer, who have had at least two lines of therapy.
